132 related articles for article (PubMed ID: 22158330)
1. A pharmacogenetic study of ADRB2 polymorphisms and indacaterol response in COPD patients.
Yelensky R; Li Y; Lewitzky S; Leroy E; Hurwitz C; Rodman D; Trifilieff A; Paulding CA
Pharmacogenomics J; 2012 Dec; 12(6):484-8. PubMed ID: 22158330
[TBL] [Abstract][Full Text] [Related]
2. β2-adrenergic receptor polymorphisms, asthma and COPD: two large population-based studies.
Thomsen M; Nordestgaard BG; Sethi AA; Tybjærg-Hansen A; Dahl M
Eur Respir J; 2012 Mar; 39(3):558-66. PubMed ID: 22075484
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of β2-agonists.
Hizawa N
Allergol Int; 2011 Sep; 60(3):239-46. PubMed ID: 21681016
[TBL] [Abstract][Full Text] [Related]
4. β(2) -adrenoreceptor polymorphisms in asthmatic and non-asthmatic schoolchildren from Colombia and their relationship to treatment response.
Isaza C; Sepúlveda-Arias JC; Agudelo BI; Arciniegas W; Henao J; Porras GL; Beltrán L
Pediatr Pulmonol; 2012 Sep; 47(9):848-55. PubMed ID: 22328447
[TBL] [Abstract][Full Text] [Related]
5. Variants of the ADRB2 Gene in COPD: Systematic Review and Meta-Analyses of Disease Risk and Treatment Response.
Nielsen AO; Jensen CS; Arredouani MS; Dahl R; Dahl M
COPD; 2017 Aug; 14(4):451-460. PubMed ID: 28506092
[TBL] [Abstract][Full Text] [Related]
6. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD.
Beeh KM; Wagner F; Khindri S; Drollmann AF
COPD; 2011 Oct; 8(5):340-5. PubMed ID: 21793716
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies.
Gotfried MH; Kerwin EM; Lawrence D; Lassen C; Kramer B
COPD; 2012 Dec; 9(6):629-36. PubMed ID: 23020650
[TBL] [Abstract][Full Text] [Related]
9. Effect of polymorphisms in the β2-adrenergic receptor on the susceptibility and pulmonary function of patients with chronic obstructive pulmonary disease: a meta analysis.
Niu LM; Liang Y; Xu M; Zhang YY; Zhang Y; He B
Chin Med J (Engl); 2012 Jun; 125(12):2213-8. PubMed ID: 22884155
[TBL] [Abstract][Full Text] [Related]
10. ADRB2 polymorphisms and asthma susceptibility: transmission disequilibrium test and meta-analysis.
Migita O; Noguchi E; Jian Z; Shibasaki M; Migita T; Ichikawa K; Matsui A; Arinami T
Int Arch Allergy Immunol; 2004 Jun; 134(2):150-7. PubMed ID: 15153795
[TBL] [Abstract][Full Text] [Related]
11. [Medication of the month. Indacaterol (Onbrez Breezhaler) and chronic obstructive pulmonary disease].
Corhay JL; Louis R
Rev Med Liege; 2011 Sep; 66(9):498-502. PubMed ID: 21995240
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study.
Kinoshita M; Lee SH; Hang LW; Ichinose M; Hosoe M; Okino N; Prasad N; Kramer B; Fukuchi Y;
Respirology; 2012 Feb; 17(2):379-89. PubMed ID: 22122202
[TBL] [Abstract][Full Text] [Related]
13. Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases.
Beeh KM; Beier J
Adv Ther; 2009 Jul; 26(7):691-9. PubMed ID: 19609496
[TBL] [Abstract][Full Text] [Related]
14. An update on the use of indacaterol in patients with COPD.
Brienza NS; Amor-Carro O; Ramos-Barbón D
Ther Adv Respir Dis; 2011 Feb; 5(1):29-40. PubMed ID: 21059700
[TBL] [Abstract][Full Text] [Related]
15. Association Between ADRB2 Genetic Polymorphisms and the Risk of Chronic Obstructive Pulmonary Disease: A Case-Control Study in a Chinese Population.
Zhao H; Wu X; Dong CL; Wang BY; Zhao J; Cao XE
Genet Test Mol Biomarkers; 2017 Aug; 21(8):491-496. PubMed ID: 28753063
[TBL] [Abstract][Full Text] [Related]
16. Indacaterol therapy in patients with COPD not receiving other maintenance treatment.
Decramer M; Rossi A; Lawrence D; McBryan D
Respir Med; 2012 Dec; 106(12):1706-14. PubMed ID: 23031496
[TBL] [Abstract][Full Text] [Related]
17. Beta2-adrenergic receptor genetic polymorphisms and short-term bronchodilator responses in patients with COPD.
Hizawa N; Makita H; Nasuhara Y; Betsuyaku T; Itoh Y; Nagai K; Hasegawa M; Nishimura M
Chest; 2007 Nov; 132(5):1485-92. PubMed ID: 17890463
[TBL] [Abstract][Full Text] [Related]
18. Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease.
Vogelmeier C; Magnussen H; LaForce C; Owen R; Kramer B
Ther Adv Respir Dis; 2011 Oct; 5(5):345-57. PubMed ID: 21719531
[TBL] [Abstract][Full Text] [Related]
19. Indacaterol.
Donohue JF; Martinez FJ
COPD; 2011 Oct; 8(5):327-8. PubMed ID: 21936681
[No Abstract] [Full Text] [Related]
20. Polymorphisms of the beta2 adrenoreceptor gene in chronic obstructive pulmonary disease.
Vacca G; Schwabe K; Dück R; Hlawa HP; Westphal A; Pabst S; Grohé C; Gillissen A
Ther Adv Respir Dis; 2009 Feb; 3(1):3-10. PubMed ID: 19293197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
